Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT06499857
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT06499857
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06499857. Randomized; triple masking; primary purpose treatment. Start 2025-04-14 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- Acronym
- SEMINAL-AF
- Condition
- Overweight or Obesity
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Chicago
Record details
- Record id
cardio:ct-nct06499857- Content hash
618b3f32eb170f1f5b6534a36e91fccac1b92e5807db13a9aa9f5064937c7626